

ASX RELEASE

Court hearing to approve the Scheme of Arrangement

Melbourne, Australia, 17 July 2020: The second Court hearing was held in the Federal Court of Australia today to consider the Scheme of Arrangement (**Scheme**) between [Sienna Cancer Diagnostics Limited \(ASX: SDX\)](#) (“Sienna” or “the Company”) and its shareholders in relation to the proposed acquisition of all the shares in Sienna by BARD1 Life Sciences Limited (**BARD1**).

All evidence was tendered today in the Federal Court of Australia. Due to a technical glitch in the Court's video conferencing facilities, the second Court hearing has been adjourned to 9.30am on Monday, 20 July 2020 where it is expected that the final Court orders with respect to the Scheme will be delivered. Any member of the public who wishes to join or listen to the Court hearing at 9.30am on Monday 20 July 2020 should refer to the Court list published on the Federal Court of Australia website for information as to how to undertake such an appearance.

Sienna anticipates that it will be in a position to announce the final orders of the Federal Court of Australia on Monday, 20 July 2020.

ENDS.

For Further Information, please contact:

Carl Stubbings, CEO & Managing Director
Sienna Cancer Diagnostics Ltd
cstubbings@siennadiagnostics.com.au
+61 3 8288 2141

The release of this announcement was authorised by Tony Di Pietro, Company Secretary.

About Sienna Cancer Diagnostics Ltd.

Sienna is a medical technology company that develops and commercialises diagnostic tests to assist in the early and accurate diagnosis of cancer, enabling improved treatment and patient outcomes. Sienna's first product, hTERT, a test that aids in the diagnosis of bladder cancer, has been launched and is being commercialised through a growing network of distribution partners globally.

Sienna entered the global liquid biopsy market in 2019 via the strategic acquisition of a “Molecular Net” technology called SIEN-NET™. The first commercial embodiment of SIEN-NET is EXO-NET™, which has been specifically designed to purify a patient sample for cancer-associated exosomes.

The Company recently announced the signing of an exclusive worldwide licence agreement with the University of Adelaide to develop and commercialise a unique cancer probe, SubB2M, which binds to a unique sugar molecule only present in human cancers and can detect its presence in the serum of cancer patients. SubB2M has the potential to detect cancer in a range of testing modalities such as liquid biopsies, immunoassays, circulating tumor cell assays and PET imaging.